Mologen AG To Present Next Generation Of TLR9 Agonists At ASGCT 2016

BERLIN--(BUSINESS WIRE)--The biotech company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) will present pre-clinical data on its EnanDIM® technology, a new family of TLR9 agonists and so-called Immune Surveillance Reactivators (ISR), at the 19th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Washington, U.S. (4-7 May, 2016). The data show that members of the EnanDIM® family broadly activate immune cells, such as monocytes, natural killer cells (NK cells) and plasmacytoid dendritic cells (pDC), in vitro. Furthermore, the data reveal no signs of toxicity after the administration of maximal feasible doses of EnanDIM® compounds and confirm immunomodulatory effects in vivo. These results allow the conclusion that EnanDIM® ISRs have the potential for clinical development in the treatment of cancer.